Phenosense Entry HIV Drug Resistance Assay
Use
The Phenosense Entry HIV Drug Resistance Assay is useful for determining phenotypic susceptibility to enfuvirtide (Fuzeon). It aids in assessing the potential effectiveness of enfuvirtide before it is incorporated into a patient's regimen or when modifying an existing regimen that includes enfuvirtide. This test is particularly beneficial in managing HIV treatment strategies to optimize therapeutic outcomes.
Special Instructions
Not provided.
Limitations
Samples with a viral load less than 500 copies/mL are not suitable for this test. Additionally, this assay requires specific specimen handling and processing; plasma must be separated and frozen immediately after collection. High-quality plasma specimens are essential for accurate results, and improper handling, such as failure to centrifuge or non-frozen specimens, can lead to test rejection.
New York Approved
Methodology
PCR-based
Biomarkers
Enfuvirtide
Analyte
LOINC Codes
- 45182-3 - HIV Phenotyp Islt
- 45182-3 - HIV Phenotyp Islt
Result Turnaround Time
18-30 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL
Minimum Volume
1.0 mL
Container
Lavender-top (EDTA) or plasma preparation tube (PPT)
Collection Instructions
Draw blood into two 5-mL PPT (pearl top) or EDTA (lavender top) tube. Centrifuge specimen within six hours of collection. Transfer plasma to one or more polypropylene screw-capped tube(s) and freeze. Freeze immediately. Send 3 mL plasma in a screw-cap vial frozen.
Causes for Rejection
PPT not centrifuged; insufficient volume; heparinized plasma; non frozen specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |